EC approves AbbVie’s Tepkinly combination for follicular lymphoma
Pharmaceutical Technology
The EC has granted marketing authorisation for AbbVie's Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.
pharminent
July 7, 2026 (Last updated: July 7, 2026)
Pharmaceutical Technology
The EC has granted marketing authorisation for AbbVie’s Tepkinly in combination with lenalidomide and rituximab for adults with relapsed or refractory follicular lymphoma.
